The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. by Caporaso, N E et al.
Environmental HealthPerspectives
Vol. 98, pp. 101-105, 1992
The Debrisoquine Metabolic Phenotype and
DNA-based Assays: Implications of
Misclassification for the Association of Lung
Cancer and the Debrisoquine Metabolic
Phenotype
by N. E. Caporaso,1 PR G. Shields,2 M. T. Landi, G. L.
Shaw,' M. A. Tucker,' R. Hoover,1 H. Sugimura,2 A.
Weston,2 and C. C. Harris2
Debrisoquine is an antihypertensive drugthat is metabolizedby cytochromeP4502D6. Deficientmetabolism
is inherited as anautosomal recessive condition. Wepreviouslyreported in acase-control studythatextensive
metabolizers of debrisoquine were at greater risk of lung cancer compared to poor and intermediate
metabolizers. Cloning ofthe gene that encodes P4502D6 (CYP2D6) led to the identification ofboth wild-type
and mutant forms ofthe gene. Subsequently, a DNA-restriction fragment length polymorphism (RFLP) was
identified, and aSouthern hybridization-based test was developed in an attemptto define the genotype.When
the DNA-RFLP test was applied to stored DNA from our study subjects there was neither a significant
association with the metabolic phenotype nor an association with lung cancer. Further work has demon-
strated that the wild-type gene, which was characterized by a 29-kb allele, can also contain mutations that
result in nonfunctional or absent proteins. When these mutations are present, individuals exhibit the poor or
intermediate metabolizer phenotype in spite ofthe presence ofthe 29-kb putative wild-type allele. Sequence
determination ofthe mutants led to the development oftechniques to exploit the polymerase chain reaction,
which, together with Southern analysis, have been reported to detect as many as 95% ofpoor metabolizers.
This technique is being used to examine the association of the extensive metabolizer genotype with lung
cancer in the subjects from the case-control study. Preliminary results indicate a weak association between
the homozygous wild-type genotype and lung cancer; in contrast, the extensive metabolizer phenotype is
strongly associated with lung cancer in this subset. Employing this polymerase chain reaction method only,
misclassification in the genotype assignment continues to occur, and work is in progress to identify further
mutations that may account for subjects who are phenotypically poor metabolizers but possess "wild-type"
alleles. The phenotyping approach is currently more sensitive, while the genotyping method may be more
specific with regard to detection of the deficient metabolizer state in the context of population studies.
Increasing use ofgenotyping is anticipated in future studies.
Introduction
While exposure to tobacco smoke is widely accepted as
the major etiologic factor in lung cancer, there are clear
differences in individual susceptibility consistent with a
heritable component to risk. The metabolism of the anti-
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hypertensive drug debrisoquine (DBR) is under autoso-
mal genetic control (1-3), and inheritance of the trait
conferringabilityto"extensively"metabolizethedrughas
been suggested as a host susceptibility factor for lung
cancer. Studies consistent with a genetic component to
lung cancer susceptibility (4-7) and studies to test the
hypothesis of an association between DBR metabolism
and lung cancer (8-14) are reported.
In a case-control study, we tested the hypothesis that
the ability to metabolize DBR is related to lung cancer
risk. Overall, extensive metabolizers of DBR, as deter-
minedbythemetabolic ratio afteradministration ofDBR,
wereatsignificantlyelevatedriskoflungcancercompared
to poor or intermediate metabolizers (odds ratio = 7.5CAPORASO ET AL.
[95% confidence interval, 2.5-22.8]). Controls were indi-
vidualswith eitherchronic obstructive pulmonary disease
or other cancers; results were adjusted for age, race,
asbestos exposure, family history of lung cancer, and
smoking. While the results ofthe six case-control studies
(7-9,11-13,15) generally support varying degrees of asso-
ciation of susceptibility to lung cancer with this phe-
notype, in our first attempt to evaluate a genotype-lung
cancer association in the same case-control study, using a
restriction fragment length polymorphism (RFLP)
marker,wefound noevidenceforanassociation (16).While
certainXbaI allelicfragments (11.5and44kb)wereassoci-
ated with the poor metabolizer phenotype, overall the
ability ofthe various RFLP patterns to predict the phe-
notypewaspoor. Thehigh degree ofmisclassification (low
sensitivity for detecting mutations that result in deficient
ability to metabolize DBR) of this marker rendered it
unacceptableforepidemiologicinference, andthequestion
ofagenotype/lungcancerassociationremainedindetermi-
nate. Continued progress in the description of the gene
andpseudogene sequences, alongwiththeidentification of
newmutationsthataccountforthemajorityofpoormetab-
olizers, have permitted application of a polymerase chain
reaction (PCR) approach to further characterization of
the genotype (17,18). In this presententation, we compare
the degree of association based on the metabolic phe-
notype, the earlier reported RFLPmarker, and aprelimi-
nary application of a new PCR-based marker using the
method ofGough etal. (18) to asubsetof133 subjectsfrom
the case-control study and consider the relative merits of
phenotype and genotype determination in future studies.
Methods
Case-Control Study
The design and conduct of the NCI-Maryland case-
control study were described in the original study report
(15). Briefly, cases were patients with histologically con-
firmed, untreated lung canceridentified atthe University
ofMaryland and BaltimoreVeteransAdministration Hos-
pitals between 1985 and 1989. Controls consisted of
patients with chronic obstructive pulmonary disease and
subjects with othermalignancies, including cancers ofthe
colon, esophagus, stomach, andbreast, andmelanoma, but
excluding bladder cancer [because of the proposed asso-
ciationbetweenbladder cancerand DBRmetabolism (19)].
Apersonal, structured interview ofapproximately 45 min
was conducted by a trained interviewer/phlebotomist.
Subjects were excluded ifthey had hypotension, inability
to take oral medications or to be interviewed, general
anesthesia within the previous 5 days, severe renal, liver,
or medical illness, or previous diagnosis of separate pri-
mary malignancy.
Although 200 subjects were accrued in the original
study, 192 had previously undergone DBR phenotyping;
samples from 92 had previously undergone Southern
hybridization with a cDNA clone of the human CYP2D6
gene after digestion by XbaI; 133 have undergone PCR
analysis.
Laboratory Methods
Phenotype. DBR and its chief metabolite, 4-hydroxy-
DBR, were determined in an aliquot of urine using the
method of Idle et al. (20). DBR (Declinax, Roche) is an
adrenergic blocker used as an antihypertensive drug in
Canada and Europe. Following an overnight fast, 10 mg
(tracer dose) of DBR were administered orally. After the
initialvoidinghadbeendiscarded,urinewascollectedover
the next 8 hr. Nonessential medications were not given on
the morning of DBR administration; fluids and a light
breakfast were permitted 1 hr after the dose. No signifi-
cant hypotensive or other adverse reaction was noted in
the study (21).
The DBR metabolic phenotype was determined by cal-
culating the metabolic ratio, i.e., percent dose excreted as
unchanged DBR divided by percent dose excreted as
4-hydroxy-DBR. This ratio can be used to classify indi-
viduals into one ofthree categories: extensive, intermedi-
ate, and poor metabolizers of DBR. The method used for
cutpoint determination involves a mixture model to fit
threenormaldistributions tothefrequencydistributionof
metabolic ratios observed in controls. Cutpoints for the
determination were derived in blacks (extensive:
intermediate = 4.2, intermediate:poor = 26.4) and
whites (extensive:intermediate = 4.8, intermediate:poor
= 11.7) from the intersections of the three theoretical
distributions (22).
Statistical analyses were performed using the SAS
statistical analysis package (23).
Genotype. The method of Gough et al. (18), employing
PCR to characterize the 29-kb allele, identifies a base
deletionatthejunctionofintron3andexon4,whichresults
in a splice-site defect. This mutation, designated the
CYP2D6 "B", is the most common one amongpoormetab-
olizers and accounts for 75% of the alleles in this group.
Nextmost common is CYP2D6 "D, "a complete deletion of
gene, associated with the 11.5 kb XbaI haplotype and
accounting for slightly greater than 10% ofalleles in poor
metabolizers. CYP2D6 'A" (deletion in exon 5) and "C"
(singlebasepairdeletioninexon5) arelesscommonandat
least 5% of mutations are as yet uncharacterized (24).
When these point mutations are present, individuals
exhibitthe poor orintermediate metabolizerphenotype in
spite ofthe presence oftheputative 29-kbwild-type allele
(17,25,26). The PCR is used to amplify a298-bp fragment,
using primers from an area that is not homologous with
CYP2D7 and CYP2D8. Theproduct is then enzymatically
digested withBstNl (NewEngland Biolabs, MA), accord-
ingtothemanufacturers' instructions. Sampleswere ana-
lyzed by electrophoresis on agarose (2.2%) (17).
Results and Discussion
In the original case-control study, 13 poormetabolizers
were identified from among 181 subjects who had under-
gone phenotyping [89 lung cancer cases, 1 poor metabo-
lizer; 92 pooled controls, 12 poor metabolizers (15)].
GenotypingusingtheXbaI restrictionfragmentsizein an
overlapping subset of controls and normal volunteers
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(n = 80) revealed 11 poor metabolizers with the following
distribution of haplotypes: five were 29/29 homozygous,
three were 29/44, two were 29/11.5, and one was 44/16/9
[see Table 1 in Sugimura et al. (16)]. These data failed to
demonstrate that the 11.5 kb and 44 kb allele fragments
were ofvalue in identifying the deficient metabolizer phe-
notype. Finally, in a recent preliminary application of a
modification of Gough's (18) method for detection of the
intron 3/exon 4 mutation in eight poor metabolizers, 3/3
were homozygous mutant subjects, but four were wild-
type homozygous and two were heterozygotes. Mis-
classification is apparently possible with either assay, but
thePCRmethodisclearly animprovement overtheearlier
RFLP approach.
The extensivemetabolizerphenotypeis stronglyassoci-
ated with lung cancer in the original study [data not
shown, see Caporaso et al. (15)]. There was no association
between the earlier RFLP marker and lung cancer risk
(16), and there was only aweak association with the PCR-
determined genotype. An explanation of the differing
degrees of association with the different tests requires
discussion.
Fromboth atechnical and anepidemiologicperspective,
accountingforthe subjects inwhom the genotype and the
phenotype donotcorrespondisofcentralimportance. Two
general explanations for a lack ofcorrespondence are: an
influenceofthe disease state orotherdistortingfactors on
the determination of phenotype (unlikely, but difficult to
exclude owing to the case-control study design) and mis-
classification error in the genotyping assay.
With regard to the first possibility, the non-correspon-
dence ofphenotype and genotype maybe due to an effect-
cause relationship; that is, in theory, the tumor, tumor
products, or tumor treatment (although subjects in this
study were untreated) could modulate expression or mea-
surement (i.e., thephenotypingprocedure) ofthe abilityto
metabolize DBR. While studies have generally found no
effect of chemotherapy on the phenotype (27), and the
phenotype of subjects after cancer therapy has not been
altered (7,11), the possibility is difficult to totally rule out.
Table 1. Comparison ofthe merits ofphenotyping and genotyping to characterize CYP2D6 in population studies.
Consideration Phenotype Genotype
Factors that influence validity
Medications Many drugs influence the phenotype Not affected
determination (32)
Medical illness Abnormal liver or kidney function may distort Not affected
phenotyping
Degree of subject Failure to collect all timed urine or to take drug Informed consent for phlebotomy
cooperation probe distorts determination
Foods Watercress (29); others unknown Not affected
Factors that influence feasibility
Exclusions Many, due to time required to collect timed urine; Few: only gravely ill patients will be unable to
need to administer drug probe; patient safety donate small blood sample required (also, other
considerations; patient conflicts; refusals sources of DNA may be used: hair follicles,
paraffin blocks, etc.); HIV or blood precautions
Test performance
Sensitivitya Excellent Fair to good, with steady improvement expected
Specificityb Fair to very good, depending on howwell subjects Excellent
taking medications are identified and excluded
Summary
Advantages Historical role; true assessment of"biochemical Identifying heterozygotes, look for dose response;
level"; well characterized in many ethnic groups; simple; free of effect-cause bias; only means to
method ofchoice in mechanistic, validation, and study subjects who cannot halt interfering
studies in new ethnic groups medications (i.e., patients with Parkinson's
disease, schizophrenics)
Disadvantages Timed urine sample; probe drug (IND needed for Mutations still incompletely characterized; ethnic
use ofdebrisoquine in the USA); medication heterogeneity likely
interference; careful patient instruction and
cooperation required
Conclusion Declining role but still important in selected Steady increase in use likely in the future
settings
aSensitivity = truepositives/(true positives + falsenegatives); inthis case apositive is adeficientmetabolizer. Heresensitivitydoes notreferto how
well the testis able toidentifysubjectswith the disease,butonlyhowwellthetestidentifies deficientmetabolizers. The"goldstandard"isphenotyping
performed in healthy, fasting subjects, receiving no medications, an administration ofdebrisoquine, followed by 8-hr urine collection.
bSpecificity = truenegatives/(true negatives + falsepositives) ortheabilityoftesttoidentifynondiseased,wherediseased orpositives aredeficient
metabolizers, andnegatives arethemore commonextensivemetabolizers. Bythisdefinition, thespecificityofthegenotypetestisquitegoodbecause all
subjects identified with two mutant alleles are phenotypic poor metabolizers.
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This problem will be addressed directly in a study cur-
rently in progress in which early-stage lung cancer
patients are phenotyped prior to treatment and again
following surgical treatment of lung cancer. Preliminary
results from this study indicate no change in the phe-
notype following treatment (28). Alternatively, unrecog-
nized medications may have rendered phenotyping
inaccurate. Individuals who are true extensive metabo-
lizers have been misclassified in the phenotyping assay
because of failure to recognize that these subjects were
receiving a medication or dietary item capable of distort-
ing phenotyping or owing to laboratory error. We have
carefully reviewed data from questionnaires and medical
abstractsusedtospecificallycapturethisinformation, and
found that an unrecognized dietary agent (29) or medica-
tion [e.g., quinidine (30,31)] mightintheoryaccountforthe
findings, but the probability appears small.
The second possibility is that the genotype assay does
notyetrecognizeallthepossiblemutationsthatmayresult
in the poor metabolizer phenotype. While perfect corre-
spondence between the genotype and phenotype in exten-
siveandintermediate metabolizersisnotexpectedbecause
family studies have demonstrated incomplete dominance
(that is, obligate heterozygotes may have either extensive
or intermediate metabolizer phenotypes), the failure to
detect mutant alleles consistently in phenotypic poor
metabolizers is problematic. Ofthe nine poor metabolizer
subjects, three are homozygous for the mutant genotype,
two areheterozygous, andfourarewild-typehomozygous.
The presence of the latter group indicates the shortcom-
ings ofthe current assay. Further mutations may account
for the deficient metabolism phenotype in these subjects.
Itislikelythatelucidation offurthermutant alleleswillbe
required before the assay fulfills its promise as the final
arbiter ofthe question ofan association with lung cancer.
In conclusion, this preliminary examination of a new
approach to genotyping the CYP2D6 locus (DBR phe-
notype) allows certain conclusions. The genotype and
phenotype show a significant association, although com-
plete correspondence is not present. The question of the
degree of association with lung cancer is the subject of
ongoing study. Itwould be premature to drawconclusions
fromtheresults ofthe "B"mutation alone,however, itis of
interest to note that the odds ratio for risk in extensive
metabolizers (pct genotype) is similar to that which is
derived from the published case-control studies in the
aggregate [odds ratio for EM is approximately 2 (32)]. If
nondifferential misclassification is assumed, the charac-
terization of further mutations (improved sensitivity)
should adjust the point estimate upward while improve-
ments in phenotyping (i.e., recognizing and eliminating
some currently unappreciated medication which inhibits
CYP2D6) will improve specificity and would likely reduce
publishedpointestimates, derivedfromthisstudy. Finally,
welisttherelative merits ofthephenotyping andgenotyp-
ing approaches as applied to population studies in Table 1.
With certain important exceptions, we anticipate that the
advantages of genotyping will mandate increasing
reliance on this approach.
One further possibility must be mentioned. Implicit in
the previous discussion is the assumption that the "real
association" must be with the genotype rather than the
phenotype. Infact,itmaybethattheDBRmetabolicratio,
ultimately determined in the individual as a complex of
genetic and environmental factors, most accurately
reflects lung cancer susceptibility itself the consequence
oftobaccoandothercarcinogenexposures, inconcertwith
hereditary predisposition. Table 1 summarizes charac-
teristics ofthe phenotype and genotype approaches.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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